Haldipurkar Shria K, Damodharan Sudarshawn N, Rathbun Pamela, Yap Kai Lee, Wadhwani Nitin, Waanders Angela J
Division of Hematology, Oncology, Neuro-Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago.
Department of Pediatrics, Section of Hematology, Oncology, and Stem Cell Transplant, University of Chicago, Comer Children's Hospital, Chicago, IL.
J Pediatr Hematol Oncol. 2025 Apr 1;47(3):148-152. doi: 10.1097/MPH.0000000000003004. Epub 2025 Mar 3.
Atypical teratoid/rhabdoid tumors (AT/RT) are malignant central nervous system (CNS) tumors. Typically, AT/RT is classified as SMARCB1 (INI-1) deficient or as SMARCA4 (BRG1) deficient. In this case, we describe a unique case of AT/RT with a novel SMARCA4 missense variant identified on next-generation sequencing but retained expression of INI-1 and BRG-1 on immunohistochemistry. Diagnosis of the tumor and discovery of the novel SMARCA4 variant was only possible after comprehensive tumor molecular testing tailored for pediatric malignancies. This case highlights the importance of molecular genetic testing as part of a workup in neoplasms concerning for possible AT/RT.
非典型畸胎样/横纹肌样瘤(AT/RT)是恶性中枢神经系统(CNS)肿瘤。通常,AT/RT分为SMARCB1(INI-1)缺陷型或SMARCA4(BRG1)缺陷型。在此病例中,我们描述了一例独特的AT/RT病例,通过下一代测序鉴定出一种新的SMARCA4错义变体,但免疫组化显示INI-1和BRG-1表达保留。只有在针对儿童恶性肿瘤进行全面的肿瘤分子检测后,才能诊断出该肿瘤并发现新的SMARCA4变体。该病例突出了分子基因检测作为疑似AT/RT肿瘤检查一部分的重要性。